Lowest Price Guaranteed From USD 2,349
Companies Covered
165
Pages
228
View Count
8066
The global intraocular pressure devices market is expected to reach USD 2.8 billion by 2026, growing at a CAGR of 83.9%. An imbalance in the production and / or drainage of aqueous humor within the eye is known to lead to an increase in intraocular pressure (IOP). Acutely elevated IOP, a condition broadly known as ocular hypertension, may either lead to the expulsion of ocular contents through a traumatic opening or result in a number of clinical conditions / disorders including glaucoma. Currently available treatment options include ocular hypotensive medications, laser therapy and surgical interventions. However, these treatment modalities are known to be associated with a number of complications and adverse events. Amongst these, poor adherence rates are a major concern in patients who are on ocular hypotensive medications; an estimated 50% of patients do not adhere to the therapeutic regimen prescribed to them. Laser therapies are known to lose their efficacy over time. It has been observed that the disease is controlled only in around 50% of patients who have been treated with some form of laser therapy; the effect usually wears off after a period of five years. Traditional surgical procedures, such as filtration procedures, glaucoma drainage devices (GDDs) and cyclodestructive procedures, are also known to have various risks and complications associated with them. Therefore, in the current scenario, multiple challenges exist as far as the treatment of elevated IOP is concerned.
A better understanding of the complex pathways involved in aqueous humor dynamics has resulted in the identification of many novel targets for maintaining ocular homeostasis. These novel targets have led to the development of a number of innovative therapeutic options for lowering elevated IOP. Specifically, to address poor patient compliance, a number of players are developing sustained release devices (implants, punctal plugs or contact lenses) so that the patient is not required to self-medicate on a regular basis. Similarly, the landscape of surgical interventions is also witnessing a lot of change with the emergence of safer, reproducible and less invasive treatment options. These novel surgical interventions include minimally-invasive glaucoma surgery (MIGS), blebless ab externo glaucoma surgery (BAGS), ab externo bleb surgery (ABS), minimally invasive micro sclerostomy (MIMS), non-penetrating glaucoma surgery (NPGS) and non-invasive glaucoma procedure (NIGP).
The ‘Intraocular Pressure Devices Market, 2016 - 2026’ market report provides an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the intraocular pressure devices market. The focus of this market research report is on the applications of these novel treatment options, both marketed and under development, and their likely mid to long term evolution. These treatment options claim to provide consistent benefits related to IOP lowering and are anticipated to gain widespread adoption in the foreseen future.
The market research report covers various aspects of intraocular pressure devices market; some of these are outlined below:
To account for the uncertainties in the market, we have provided three market forecast scenarios that represent three different tracks of the market’s evolution. Given the current unmet need for safer and more effective therapeutic options and the rich pipeline of novel drugs and devices, we expect this intraocular pressure devices market to witness significant market growth during the forecast period.
Our opinions and insights presented in this market report were influenced by discussions conducted with several key players in intraocular pressure devices market. The market research report features detailed transcripts of interviews held with Bob Butchofsky (Founder and CEO, Mati Therapeutics), Suzana Nahum Zilberberg (CEO, Bio-Light Life Sciences), Ronen Castro (CEO, IOPtima) and Donald Schwartz (CEO and President, Eye Sonix).